Should intravenous immunoglobulin be used in infants with isoimmune haemolytic disease due to ABO incompatibility?

Amy K. Keir, Michael Dunn, Jeannie Callum

Research output: Contribution to journalArticlepeer-review

4 Citations (Scopus)

Abstract

The use of intravenous immunoglobulin in isoimmune haemolytic disease due to ABO incompatibility is recommended by the American Academy of Pediatrics and the National Blood Authority, Australia. However, the evidence these recommendations are based on appears limited and, in some instances, outdated. In our article, we review the current available literature to help answer the question, 'In infants with isoimmune haemolytic disease due to ABO incompatibility [P], does use of intravenous immunoglobulin and intensive phototherapy [I] compared with intensive phototherapy alone [C] provide any clinically important benefits [O]?'

Original languageEnglish
Pages (from-to)1072-1078
Number of pages7
JournalJournal of Paediatrics and Child Health
Volume49
Issue number12
DOIs
Publication statusPublished - 1 Dec 2013

Keywords

  • anaemia
  • haemolytic
  • hyperbilirubinaemia
  • immunoglobulin
  • infant
  • newborn

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this